Table 2.
Eukaryotic (hEVs) | Bacterial (bEVs) | Common Limitations |
---|---|---|
Differentiation between cell surface markers | Lipopolysaccharide (LPS) toxicity | Immunomodulators outburst |
Inefficient purification of vesicles | High inflammatory responses | Low viability and inefficient growth conditions |
Lack of heterogeneity | High chance of infection (pathogen-derived bEVs) |
High cellular toxicity |